Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, AnchorDx to Develop Genomic Cancer Tests for Chinese Market

NEW YORK – Illumina said yesterday that it has partnered with Chinese molecular diagnostics firm AnchorDx to develop clinical oncology tests for the Chinese market.

Under the terms of the strategic collaboration, AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencing system to develop in vitro diagnostic cancer test kits and data analysis software. AnchorDx plans to develop genomic cancer tests that range from screening to diagnostic testing to treatment monitoring.

One focus of the collaboration will be to improve early cancer detection, with the goal of developing the first cancer screening IVD product in China on the MiSeqDx system, which is approved by China's National Medical Products Administration (NMPA).

"This collaboration highlights Illumina's recognition of AnchorDx's capabilities in research and development, clinical development, and marketing," said AnchorDx CEO Jian Bing Fan, a former Illumina employee, in a statement.

In 2017, AnchorDx raised $28 million in a Series B funding round to develop next-generation sequencing-based oncology products.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.